147 related articles for article (PubMed ID: 38164232)
1. Unmasking Coincident Hodgkin Lymphoma and Giant Cell Tumor: Insights from [
Al-Ibraheem A; Moghrabi S; Abdlkadir AS; Haidar M; Jaber O
Asia Ocean J Nucl Med Biol; 2024; 12(1):57-60. PubMed ID: 38164232
[TBL] [Abstract][Full Text] [Related]
2. Tenosynovial giant cell tumors in unusual locations detected by positron emission tomography imaging confused with malignant tumors: report of two cases.
Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Takahira M; Fukui K; Oikawa T; Tsuchiya H
BMC Musculoskelet Disord; 2016 Apr; 17():180. PubMed ID: 27113721
[TBL] [Abstract][Full Text] [Related]
3. Diffuse-Type Tenosynovial Giant Cell Tumor of the Shoulder Evaluated by FDG PET/CT.
Tang K; Zheng X; Lin J; Wang L
Clin Nucl Med; 2019 Apr; 44(4):310-312. PubMed ID: 30624274
[TBL] [Abstract][Full Text] [Related]
4. PET/CT: Clinical role in lymphomas.
Papathanasiou N
Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
[No Abstract] [Full Text] [Related]
5. Imaging characteristics of tenosynovial giant cell tumors on
Mizuta K; Oshiro H; Tsuha Y; Tome Y; Nishida K
BMC Musculoskelet Disord; 2023 Jul; 24(1):593. PubMed ID: 37468883
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT in Tenosynovial Giant Cell Tumor of the Lumbar Facet Joint.
Zhang J; Li Y; Zhu Y; Duan Y; Zhu Y
Clin Nucl Med; 2022 Jan; 47(1):66-67. PubMed ID: 34034325
[TBL] [Abstract][Full Text] [Related]
7. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
9.
He Q; Xiao L; Li Y
Hell J Nucl Med; 2023; 26(1):73-74. PubMed ID: 37031425
[TBL] [Abstract][Full Text] [Related]
10. Tenosynovial giant cell tumor: a case report.
Ansel S; Yan X; Chong P; Lo S; McCleery M; Mahendra A; MacDuff E; Cowie F; Nixon I; White J;
J Med Case Rep; 2023 Oct; 17(1):419. PubMed ID: 37798760
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
13. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.
Moulin-Romsee G; Hindié E; Cuenca X; Brice P; Decaudin D; Bénamor M; Brière J; Anitei M; Filmont JE; Sibon D; de Kerviler E; Moretti JL
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1095-105. PubMed ID: 20204358
[TBL] [Abstract][Full Text] [Related]
15. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
16. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
17.
Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report.
Ren Y; Huang L; Han Y; Cui Z; Li J; Dong C; Liu J
Medicine (Baltimore); 2019 Feb; 98(5):e14270. PubMed ID: 30702589
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
[TBL] [Abstract][Full Text] [Related]
20. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
